The vacuolar protein sorting protein 41 (VPS41) is a neuroprotective protein in models of Parkinson's disease (PD). As part of the HOPS (Homotypic fusion and Protein Sorting) complex, VPS41 regulates fusion of lysosomes with late endosomes and autophagosomes. Independent of HOPS, VPS41 regulates transport of newly synthesized lysosomal membrane proteins and secretory proteins. Here we report two brothers with compound heterozygous mutations in VPS41 (VPS41 R662* and VPS41 S285P ), born to healthy and non-consanguineous parents. Both patients displayed transient retinal dystrophy, ataxia and dystonia, with brain MRI findings of cerebellar atrophy and a thin saber-shape corpus callosum. Patient-derived fibroblasts contained enzymatically active lysosomes that were poorly reached by endocytic cargo and failed to attract the mTORC1 complex. Consequently, transcription factor TFE3, a driver of autophagy and lysosomal genes, showed continuous nuclear localization which resulted in elevated LC3-II levels and an impaired response to nutrient starvation. CRISPR/CAS VPS41 HeLa knockout cells showed a similar phenotype that could be rescued by wildtype VPS41 but not by VPS41 S285P or VPS41 R662* . mTORC1 inhibition was also seen after knockout of HOPS subunits VPS11 or VPS18. Regulated neuropeptide secretion in PC12 VPS41 knockout cells was rescued by VPS41 S285P expression, indicating that this HOPS-independent function was preserved. Co-expression of the VPS41 S285P and VPS41 R662* variants in a C. elegans model of PD abolished the protective effect of VPS41 against α-synuclein-induced neurodegeneration. We conclude that both disease-associated VPS41 variants specifically abrogate HOPS function, which leads to a delay in endocytic cargo delivery to lysosomes, mTORC1 inhibition and irresponsiveness to autophagic clues. Our studies signify a link between HOPS function and mTORC1 signaling and imply that HOPS function is required for the neuroprotective effect of VPS41 in PD.
Introduction
While lysosomes are responsible for the degradation and recycling of intra-and extracellular substrates (1) , they are increasingly recognized as regulators of cellular homeostasis and key players in nutrient sensing and transcriptional regulation (2) (3) (4) (5) . Hence, the digestive properties of lysosomes give them a major role in the control of cellular metabolism and nutrient homeostasis. To accomplish this, HOPS (Homotypic Fusion and Protein Sorting) regulates fusion of lysosomes with endosomes and autophagosomes (6) (7) (8) (9) (10) (11) .
Vacuolar Protein Sorting 41 (VPS41) (Chr7p14.1), a defining component of HOPS, is a 100 kD protein that contains a WD40, TRP-like (tetratricopeptide repeat), CHCR (Clathrin Heavy Chain Repeat) and RING (Really Interesting New Gene)-H2 Zinc Finger domain (12, 13) . VPS41 knockout mice die early in utero, defining VPS41 as an essential protein for embryonic development (14) . HOPS-associated VPS41 is recruited to endosomes by binding to Rab7 and its interactor protein RILP and to lysosomes by interacting with Arf-like protein 8b (Arl8b) (15, 16) . Depletion of VPS41 impairs HOPS dependent delivery of endocytic cargo to lysosomes and causes a defect in autophagosomal flux (6, 17) .
Independent of HOPS, VPS41 is required for transport of lysosomal membrane proteins from the trans-Golgi-Network (TGN) to lysosomes (18) , (19) , a pathway known as the Alkaline Phosphatase (ALP) pathway in yeast (20) (21) (22) (23) (24) . Furthermore, in secretory cells and neurons, VPS41 is required for regulated secretion of neuropeptides (25) (26) (27) (28) (29) (30) (31) . Both in yeast and in secretory cells it was suggested that VPS41 forms a coat on adaptor protein 3 (AP-3) containing membranes that exit the TGN (23, 24, 31) . Together these data show that VPS41, as part of HOPS, is required for lysosomal fusion events and, independent of HOPS, for transport of lysosomal membrane proteins and regulated secretion.
Interestingly, VPS41 overexpression protects dopaminergic neurons against neurodegeneration in a transgenic C. elegans model of Parkinson's Disease (PD), in which α-synuclein is locally overexpressed (32) (33) (34) . Similarly, when VPS41 is overexpressed in human neuroglioma cells, α-synuclein protein levels are reduced (32) . This neuroprotective effect requires interactions of VPS41 with Rab7 and AP- 3(35) . Recent studies using a C. elegans model for Alzheimer's disease showed that overexpression of human VPS41 also mitigates Aβ-induced neurodegeneration of glutamatergic neurons. This requires Arl8 activity rather than Rab7 and AP3, indicating that VPS41 through different interaction partners can trigger divergent neuroprotective mechanisms(35). However, how VPS41 function leads to neuroprotection remains to be elucidated. Naturally occurring SNPs in VPS41 have been described (T52R, T146P and A187T) (32, 36) , but thus far no patients bearing mutations in VPS41 were identified. In this study, we present brothers with severe neurological features (e.g. transient retinal dystrophy, ataxia and dystonia accompanied by retinal dystrophy and mental retardation with brain MRI findings of cerebellar atrophy and thin corpus callosum) of unknown aetiology. Exome sequencing showed that both patients were compound 5 heterozygous for variants in VPS41 [NM_014396. 19 : c.853T>C, NP_055211.2: pSer285Pro (S285P); NM_014396.6: c.1984C>T, NP_055211.2: pArg662Stop (R662*)]. To our best knowledge, this is the first report of patients bearing biallelic VPS41 variants displaying neurological manifestations. We show that the VPS41 variants in patient cells prevents formation of the HOPS complex, leading to a defect in the delivery of endocytosed and autophagic cargo to lysosomes, inhibition of the mTORC1 complex, and a constitutive upregulation of autophagy. This renders cells unable to respond to changes in nutrient conditions and abolishes the neuroprotective effect of VPS41 in a C. elegans model of PD.
Results

Clinical presentation of two patients with biallelic mutations in VPS41
Two brothers, born to healthy and non-consanguineous parents, were noted to be hypotonic shortly after birth. In infancy they showed global developmental delay, low muscle tone, and marked tremor which further impaired their fine motor skills. Both brothers showed absent deep tendon reflexes (DTRs) and their plantars were extensor. Both patients developed upper extremity tremor and significant lower limbs' ataxia and spastic ataxia. Brain MRI in both cases showed mild hypomyelination ( Figure 1A, B ). Brain MRI studies of the younger brother (patient 2) revealed mild hypoplasia of the cerebellum and cerebellar vermis and a thin corpus callosum. A repeat brain MRI at 10 years of age confirmed the thin corpus callosum, mild progression of the cerebellar atrophy, bilateral hypointensity in the globus pallidus (GP) compatible with early iron deposition, as well as abnormal hyperintensity in the dentate nucleus and cerebellar cortex ( Figure 1B ). Analyses of genes known to cause X-linked mental retardation and dystonia as well as genes associated with iron deposition in the basal ganglia were tested but no mutations were found (Table S1 ). Whole exome sequencing performed on both patients revealed compound heterozygote variants in VPS41.
Each of the parents was found to be heterozygote for a variant in the VPS41 gene; the father carries a point mutation in the WD40 domain (NM_014396. 19 : c.853T>C, NP_055211.2: pSer285Pro, hereafter referred to as VPS41 S285P ), the mother carries a nonsense mutation in the Clathrin Heavy Chain Repeat (CHCR) resulting in a truncated protein (NM_014396.6: c.1984C>T, NP_055211.2: pArg662Stop; hereafter referred to as VPS41 R662* ) ( Figure S1 ).
Patient fibroblasts and VPS41 KO cells contain small-sized, acidified lysosomes active for cathepsin B
To study the cellular effects of the VPS41 variants we obtained skin biopsies from the youngest brother (case 2) (VPS41 S285P/R662* ), an independent control (VPS41 WT/WT ), the patients' father (VPS41 WT/S285P ) and the patients' mother (VPS41 WT/R662* ) and made primary fibroblast cultures. Since the older brother was found to have a de novo duplication at Chr1q21.1 of unknown significance (Supplemental information), only fibroblasts of the second patients were obtained. First we studied the effects of the mutations on lysosomal biogenesis and function. Electron microscopy (EM) showed a high variation in appearance of endo-lysosomal compartments in primary fibroblasts ( Figure S2 ), but no swollen lysosomes in the patient-derived cells. This indicates that the patient-specific mutations in VPS41 do not cause a classical lysosomal storage phenotype (37) . To study lysosomal acidification and hydrolase activity we performed fluorescence microscopy using lysotracker-Green and MagicRed-cathepsin B. This showed an increase in the number of acidic and cathepsin B-active puncta in patient fibroblasts as compared to control or parental cells ( Figure S3A , quantified in S3A'). Concomitantly, immunofluorescence of the lysosomal membrane protein LAMP-1 showed twice as much puncta in patient cells (Figure 2A LAMP-1 resides in lysosomes as well as late endosomes, which by EM are distinguished by the presence or absence of degraded material, respectively (38) (39) (40) (41) . By immuno-EM we found that VPS41 S285P/R662* fibroblasts contain numerous LAMP-1 positive late endosomes and lysosomes which are positive for cathepsin B (Figures 2D and Figure S3C ), but that the lysosomes are significantly smaller than in VPS41 WT/WT , VPS41 WT/S285P or VPS41 WT/R662* fibroblasts ( Figure 2E ). The relative labeling density of LAMP-1 in the lysosomal membrane remained equivalent to control cells ( Figure 2F ), but since lysosomes were smaller the absolute number of gold particles per lysosome had decreased ( Figure 2G ). Similar data were obtained for LAMP-2 ( Figure S4A and B). We conclude from these data that the biallelic VPS41 R662* and VPS41 S285P variants induce the presence of small-sized, enzymatically-active lysosomes, which at steady state conditions contain normal LAMP levels.
VPS41 R662* poorly interacts with other HOPS subunits
To understand the effects of the VPS41 mutations at the molecular level, we investigated the ability of VPS41 R662* and VPS41 S285P to interact with other subunits of the HOPS complex. Hereto we performed co-immunoprecipitation (co-IP) studies in HeLa cells expressing GFP-tagged constructs of VPS41 WT , VPS41 S285P or VPS41 R662* and respectively FLAG-and HA-tagged constructs of VPS18 or VPS33A.
Expression of all constructs was readily detectable by Western blot ( Figure 3A and S5). The premature stop codon in VPS41 R662* resulted in a truncated protein of lower molecular weight. VPS41 S285P interacted with both VPS18 and VPS33A, but interaction of VPS41 R662* with the other HOPS subunits was strongly reduced ( Figure 3A and S5). Since interaction between VPS41 and VPS18 requires the presence of the C-terminal RING domains that is absent from VPS41 R662* ( Figure S1 ), these data are in agreement with present literature (42) .
Truncated proteins are often prematurely degraded. To test this for VPS41 R662* , we analyzed the expression levels of the VPS41 variants in primary fibroblasts by Western Blot. Full length VPS41, representing both VPS41 WT and VPS41 S285P , was readily detectable. However, no VPS41 R662* was seen in either VPS41 WT/R662* maternal or VPS41 S285P/R662* patient fibroblasts ( Figure 3B ). Since the antibody does recognize truncated VPS41 R662* when overexpressed ( Figure 3A and S5), we conclude that VPS41 R662* protein levels are below detection in primary fibroblasts derived from the patient and mother. Of note, VPS41 expression levels are higher in a.o. neuronal cell types (https://www.proteinatlas.org/ENSG00000006715-VPS41/), which renders it possible that other cell types in the patients express residual levels of VPS41 R662* .
Together these experiments show that VPS41 R662* is unable to bind other HOPS components whereas VPS41 S285P binds VPS18 and VPS33A. Also, VPS41 R662* shows an overall low expression level.
VPS41 S285P and VPS41 R662* both cause a defect in late endosome -lysosome fusion
Depletion of VPS41 by RNAi results in a decrease in HOPS-dependent fusion between late endosomes and lysosomes (6, 19) . To establish the effect of the individual VPS41 mutants on HOPS function, we transiently transfected HeLa VPS41KO cells with APEX2-V5 tagged constructs of VPS41 WT , VPS41 S285P or VPS41 R662* . The subcellular distribution of these constructs was explored by immunofluorescence microscopy. VPS41 WT was found dispersed in the cytoplasm as well as in distinct fluorescent puncta that co-localized with LAMP-1, consistent with previous studies (16, 43) ( Figure 3C ). Remarkably, both VPS41 S285P and VPS41 R662* showed a similar distribution as VPS41 WT , despite the lack of the C-terminus in VPS41 R662* . To address the mechanism of membrane association of VPS41 we performed co-IP's using APEX-V5-tagged VPS41 constructs and FLAG and GFP-tagged constructs of Arl8b and Rab7. This showed that VPS41 R662* binds Rab7 and Arl8 to the same extent as VPS41 WT and VPS41 S285P ( Figure 3D ).
These data indicate that Rab7 and Arl8b can recruit VPS41 R662* to late endosomes and lysosomes independent of its incorporation in the HOPS complex or presence of the C-terminus.
To test whether either of the mutants allows for HOPS function, VPS41 KO cells were incubated for 2 hours with the endocytic marker Dextran-ALEXA568 and SiR-Lysosome to mark active cathepsin D compartments. Co-localization between these probes indicates the transfer of endocytosed cargo to enzymatically active lysosomes. VPS41 KO cells transfected with Empty Vector (EV) showed low levels of co-localization ( Figure 3E and Figure S6A ). Transfection with VPS41 WT increased co-localization, indicating a restoration of HOPS function ( Figure S6A ). Transfection with VPS41 R662* did not rescue the endocytosis defect, which was expected since VPS41 R662* fails to bind other HOPS components (Figure   3A) . Surprisingly, however, VPS41 S285P also failed to rescue the endocytosis defect ( Figure 3E and Figure   S6 ). Thus, even though VPS41 S285P binds VPS18 and VPS33A ( Figure 3A and Figure S5 ) and localizes to endo-lysosomes ( Figure 3C ) it cannot form a functional HOPS complex. A plausible explanation is misfolding of the protein due to the Arginine to Proline substitution, which is predicted to cause a conformation change (http://genetics.bwh.harvard.edu/pph2/) (44) . Concluding, these data indicate that neither VPS41 variant allows formation of a functional HOPS complex.
Patient fibroblasts are compromised in delivery of endocytosed cargo to enzymatically active lysosomes
To assess the process of late endosome -lysosome fusion in patient cells we applied the Dextran-ALEXA568 and SiR-Lysosome cathepsin D colocalization assay to the primary fibroblast cultures. This confirmed an endocytosis defect in VPS41 S285P/R662* (patient) fibroblasts. Notably, however, also the maternal VPS41 WT/R662* cells showed a decreased co-localization of Dextran-ALEXA568 and SiR-Lysosome cathepsin D. By contrast, VPS41 WT/S285P (paternal) fibroblasts were not affected in endocytosis ( Figure 3F and Figure S6B ). To investigate the block in endocytosis at the EM level, we incubated primary fibroblasts for 2 hours with BSA conjugated to 5 nm gold particles (BSA-Au 5 ) and processed cells for immuno-EM. Sections were labeled for LAMP-1 or LAMP-2 and randomly screened for LAMP-positive lysosomes(40) ( Figure 2D ), which were scored positive or negative for BSA-Au 5 . This showed a strong decrease in the delivery of BSA-Au 5 to LAMP-positive lysosomes of patient fibroblasts ( Figure 3G ). In agreement with the fluorescent data the maternal VPS41 WT/R662* fibroblasts also showed a decrease in BSA-Au 5 -positive lysosomes, whereas the paternal VPS41 WT/S285P fibroblasts were not affected. Together these data show that in patient fibroblasts the delivery of endocytosed cargo to enzymatically active lysosomes is delayed, which is explained by that neither VPS41 variant allows formation of a functional HOPS complex ( Figure 3E ). The endocytic delay observed in the maternal fibroblasts, indicates that in this case the defect is not fully compensated for by the VPS41 WT allele.
Loss of VPS41 WT causes a defect in autophagic response to starvation
In addition to late endosome-lysosome fusion, the HOPS complex is required for fusion of autophagosomes with lysosomes (45) (46) (47) . A block in autophagosome-lysosome fusion is predicted to result in increased numbers of autophagosomes containing lipidated LC3 (LC3-II). We addressed LC3-II levels in the primary fibroblast cultures by Western blotting. In nutrient-rich conditions LC3-II levels in VPS41 S285P/R662* (patient) fibroblasts were similar to control and parental cells ( Figure 4A , quantified in 4A'). However, when autophagy was induced by nutrient starvation, LC3-II levels in VPS41 WT/WT , VPS41 WT/S285P and VPS41 WT/R662* fibroblasts strongly increased to 150-200% of the original levels, whereas in patient fibroblasts only a mild, 40%, increase was seen. This shows an inability of patient fibroblasts to respond to nutrient starvation via upregulation of autophagy. Thus, although we do not see an increase of LC3 in steady state levels, the patient fibroblasts show a clear defect in regulation of the autophagy response.
To better understand this phenomenon we studied autophagy in HeLa VPS41KO cells. When grown under nutrient-rich conditions LC3-II levels in these cells were significantly elevated compared to HeLa WT cells ( Figure 4B , quantified in 4B'). This is in contrast to our observations in patient fibroblasts, but similar to previous results in VPS41-depleted HeLa cells 54 and our non-published observations in A549 and PC12 VPS41 KO cells (data not shown). Immunofluorescence on HeLa VPS41KO cells also showed more LC3 puncta, indicative for the increase in number of autophagosomes ( Figure 4C , quantified in 4C'). We then transfected HeLa WT and VPS41 KO cells with an LC3 GFP/RFP tandem construct. The GFP and RFP signals co-label autophagosomes, but the GFP signal is lost after autophagosome -lysosome fusion (48) . VPS41 KO cells showed a significant higher percentage of GFP/RFP co-localization, indicating that in the absence of VPS41, autophagosome -lysosome fusion is impaired ( Figure 4D , quantified in 4D'), resulting in more LC3 puncta. Strikingly, starvation of HeLa VPS41KO cells did not further increase LC3-II protein levels or number of LC3 puncta ( Figure 4B and 4C), which exactly mimics the unresponsiveness of patient fibroblasts to starvation. Rescue of HeLa VPS41KO cells with VPS41 WT reduced the number of LC3 puncta and restored the capacity of cells to react to starvation and restimulation ( Figure 4C ). By contrast, expression of VPS41 S285P or VPS41 R662* did not restore the autophagy phenotype ( Figure 4C ). This shows that both VPS41 variants are unable to restore basal autophagy levels and provoke an inability to react to nutrient starvation.
We conclude from these data that patient fibroblasts, VPS41 KO cells or VPS41 KO cells expressing VPS41 S285P or VPS41 R662* have multiple defects in autophagy; a decrease in autophagosome -lysosome fusion and a decreased ability to raise LC3-II levels after starvation. Concomitantly, VPS41 KO cells display higher LC3-II levels and contain more autophagosomes under steady state conditions. Patient fibroblasts do not show a markable increase in LC3-II, but this is possibly obscured by the high variation between these primary cultured cells. Alternatively, compensatory mechanisms may have developed.
The autophagy defect is specific for the patient derived fibroblasts and not observed in any of the parental cell lines, indicative that this phenomenon is important for disease development.
VPS41 deficiency causes mTORC1 inhibition
A complex of v-ATPase/Ragulator/Rag GTPases present at the lysosomal membrane senses nutrient status in lysosomes and, in nutrient-rich conditions, recruits the mammalian target of rapamycin complex 1 (mTORC1). Upon nutrient deprivation, mTORC1 dissociates from the lysosomal membrane and loses its kinase activity. Consequently, transcription factors TFEB and TFE3, substrates of mTORC1, translocate to the nucleus where they activate the CLEAR (Coordinated Lysosomal Expression and Regulation) network that induces lysosomal biogenesis and autophagy (49) . LC3 is a target of the CLEAR network and mTORC1 inhibition results in enhanced LC3 levels (49) . Since patient derived fibroblasts and VPS41 KO cells are less responsive to starvation ( Figure 4A -C) this prompted us to investigate mTORC1 activity in VPS41 patient fibroblasts and KO cells.
We first studied the recruitment of mTORC1 to lysosomal membranes by monitoring colocalization with LAMP-1. Immunofluorescence of VPS41 S285P/R662* patient fibroblasts grown in nutrient-rich conditions showed a striking decrease in localization of mTORC1 to LAMP-1-positive puncta when compared to control or parental cells ( Figure 5A and Figure S7 , quantified in 5A'). In healthy cells, starvation induces mTORC1 dissociation from lysosomes, whereas restimulation with complete medium restores membrane association. Indeed, in control VPS41 WT/WT , paternal VPS41 WT/S285P and maternal VPS41 WT/R662* fibroblasts, mTORC1 dissociated from LAMP-1 positive lysosomes upon 2 hours starvation and partially re-localized after 15 min restimulation. By contrast, mTORC1 localization in VPS41 S285P/R662* patient fibroblasts did not change upon starvation or restimulation ( Figure 5A , quantified in 5A'). To test the effect of mTORC1 dissociation on TFEB/TFE3 localization we performed immunofluorescence microscopy of TFE3, which allows for detection of endogenous TFE3. This showed that TFE3 was continuously present in the nucleus of patient cells, regardless of nutrient status. By contrast, VPS41 WT/WT , VPS41 WT/S285P and VPS41 WT/R662* fibroblasts only showed nuclear TFE3 localization in response to starvation ( Figure 5B , quantified in 5B'). These data indicate that in patient cells mTORC1 is strongly inhibited and TFE3 is continuously activated, which predicts an increase in expression of lysosomal and autophagy proteins (50, 51) . Western Blot analysis indeed showed that in addition to LC3, protein levels of LAMP-1 and the lysosomal hydrolase cathepsin B were increased in patient's fibroblasts ( Figure S8 ).
When similar experiments were performed on HeLa VPS41KO cells we also found a decreased lysosomal localization of mTORC1 ( Figure 5C ) and continuous nuclear localization of TFE3, independent of nutrient status ( Figure 5D ). We further refer to this pattern as the mTORC1/TFE3 phenotype.
Expression of VPS41 WT in HeLa VPS41KO cells rescued this phenotype after restimulation, whereas expression of VPS41 S285P or VPS41 R662* had no effect ( Figure 5D , quantified in 5D'), inferring that neither of the VPS41 variants could rescue the mTORC1/TFE3 phenotype. These data show that cells lacking VPS41 or expressing VPS41 S285P and/or VPS41 R662* , mTORC1 dissociates from lysosomes.
A possible explanation for the mTORC1/TFE3 phenotype is that the defect in HOPS function results in insufficient delivery of nutrients to lysosomes, resulting in nutrient depletion and subsequent mTORC1 dissociation. If so, any block in HOPS function should give a similar phenotype. To test this we made HeLa KO cells for VPS11 and VPS18, which are part of HOPS but not required for the ALP/LAMP pathway (18) . Both KO cell lines showed increased LC3-II protein levels in basal conditions and a constitutive nuclear localization of TFE3, independent of nutrient status ( Figure S9A and S9B, quantified in S9B').
We conclude from these data that heterologous expression of VPS41 S285P and VPS41 R662* or complete KO of VPS41 results in the dissociation of mTORC1 from lysosomes, a subsequent nuclear localization of TFE3 and increased expression of LC3-II. Moreover, these cells lose the ability to respond to starvation. The mTORC1 inhibition is likely caused by a lack of HOPS function, since depletion of other HOPS subunits result in a similar phenotype.
VPS41 S285P allows for normal regulated secretion in PC12 cells
VPS41 is required for secretory protein sorting and secretory granule biogenesis in a pathway that is independent of the HOPS complex (31) . This VPS41 function requires the N-terminal residues 1-36 for interaction with AP-3 and the presence of the C-terminal located CHCR domain (31, 52) . Since the VPS41 R662* variant lacks both the RING domain and part of the CHCR domain, a function in regulated secretion is excluded (31) . However, the VPS41 S285P mutant could theoretically still exert this HOPS independent function. To test this, we first investigated whether VPS41 S285P can interact with AP-3.
Pulldowns of recombinant VPS41 constructs with the hinge-ear domain of AP3D1 showed that 12 VPS41 S285P binds AP-3 with equivalent affinity as VPS41 WT (Figure 6A , S10). To directly test the effect of VPS41 S285P on regulated secretion, we performed secretion experiments using VPS41 KO PC12 cells in which we reintroduced either VPS41 WT or VPS41 S285P . Regulated protein secretion was measured as previously described (30) . Briefly, cells were incubated in Tyrode's buffer containing 2.5 mM (basal) or 90 mM (stimulated) K+ and the supernatant and cell lysates were analyzed by quantitative fluorescent immunoblotting. This unequivocally showed that VPS41 S285P rescued secretion to the same extent as VPS41 WT (Figure 6B -D). As previously showed (31) , cellular SgII protein levels were decreased in VPS41 KO cells. Reintroduction of VPS41 WT or VPS41 S285P resulted in an increase in these cellular SgII levels.
Together these data show that VPS41 S285P binds AP-3 and rescues the regulated secretory pathway in VPS41 KO PC12 cells indicating that the HOPS-independent function of VPS41 S285P is not affected.
Co-expression of VPS41 S285 and VPS41 R662* abolishes neuroprotective function in a C. elegans model of Parkinson's disease
The clinical symptoms of the two VPS41 patients ( Figure 1 ) overlap with PD (53, 54) . Previously, a screen for neuroprotective factors in a transgenic C. elegans model for PD showed that overexpression of human VPS41 protects against α-synuclein induced neurodegeneration (32) (33) (34) . The neuroprotective effect of VPS41 depends on the presence of the WD40 and CHCR domains and ability to interact with Rab7 and AP-3 (32, 35) . To explore the impact of the disease-causing VPS41 S285P and VPS41 R662* mutants in this PD model, we made transgenic nematodes co-expressing pairs of human VPS41 isoforms (hVPS41) in dopaminergic neurons and crossed these with isogenic strains overexpressing either GFP alone or together with human α-synuclein to mimic PD.
First we combined VPS41 WT with VPS41 S285P or VPS41 R662 expression, reflecting paternal and maternal conditions, and studied the effect on neurodegeneration in the absence of α-synuclein. At 7 or 10 days post-hatching, there was no statistically significant change in neurodegeneration in any of these strains ( Figure 7A,B) . Likewise, when we co-expressed VPS41 S285P with VPS41 R662* there was no discernable increase in neurodegeneration. This demonstrates that co-expression of the two patient-specific hVPS41 variants by itself does not increase neurodegeneration in (ageing) animals.
We then analyzed VPS41 neuroprotective function in the strains overexpressing α-synuclein. At 7 days post-hatching, only ~43% of the animal population overexpressing α-synuclein retained the full complement of dopaminergic neurons. By 10 days, this had decreased to only ~33% of the population.
Co-expression of VPS41 WT with either VPS41 S285P or VPS41 R662* significantly enhanced the neuroprotection at 7 days post-hatching, but at day 10 the protective effect was lost ( Figure 7C ,D).
By contrast, animals co-expressing VPS41 S285P and VPS41 R662* , reflecting patient conditions, showed no protective effect at all at either day 7 or 10 ( Figure 7C,D) . Therefore, the protective effect observed with the compound heterozygous combinations is lost as animals age. By contrast, expression of 13 VPS41 WT alone rescues neurodegeneration also at day 10, albeit it with reduced efficiency compared to day 7 (32, 34) . Moreover, neuroprotection at day 10 was significantly diminished in worms coexpressing both of the clinical VPS41 variants in combination indicating additional stress besides αsynuclein overexpressing and aging alone. These data collectively indicate that the neuroprotective capacity of VPS41 is differentially impacted by genetic composition.
Discussion
The vacuolar protein sorting-associated protein 41 (VPS41) has a major contribution in the vesiclemediated trafficking to lysosomal compartments including endocytic transport and the autophagic pathway. VPS41 is part of the HOPS complex, a multisubunit tethering complex which mediates fusion of lysosomes with late endosome and autophagosomes (12, 13) . Independently of the HOPS complex, VPS41 is also involved in the transport of lysosomal membrane proteins from the Trans-Golgi network independently of HOPS (18) , and plays a role in regulated secretion of neuropeptides (31) . VPS41 is previously identified as neuroprotector in C. elegans and mammalian models of Parkinson's Disease (PD) (32, 34, 35) . However, to our best knowledge, no specific human condition has been reported in association with a pathogenic variant in VPS41. We here report on two siblings with compound heterozygote variants in VPS41 and show the implications of these variants on a cellular level. We show that both VPS41 variants result in a nonfunctional HOPS complex, causing a defect in the delivery of endocytic and autophagy cargo to enzymatically active lysosomes. Most strikingly, VPS41 dysfunction causes dissociation of the mTORC1 complex from lysosomes which renders cells unable to respond to nutrient starvation and results in increased autophagy levels. Our studies thereby for the first time link HOPS complex functionality to mTORC1 signaling.
The patients, two brothers, were diagnosed with global developmental delay, hypotonia, ataxia and dystonia. By exome sequencing we identified a missense mutation in the WD40 domain (VPS41 S285P ), and a nonsense mutation in the CHCR domain resulting in a premature stopcodon (VPS41 R662* ). Neither VPS41 mutant forms a functional HOPS complex, indicating that the patient cells lack HOPS functionality. The R662* variant lost binding affinity to HOPS components VPS18 or VPS33A due to a lack of the RING domain (42) , yet was recruited to late endosomes and lysosomes by interaction with Rab7 and Arl8b. These data imply that recruitment of VPS41 to endo-lysosomal membranes does not require HOPS complex incorporation. However, VPS41 R662* is not expressed in patient cells, indicating that the disease phenotype is caused by the VPS41 S285P mutation solely. VPS41 S285P interacted with other HOPS complex subunits and was recruited to LAMP-1 positive endo-lysosomal membranes, but did not rescue the fusion defect in VPS41 KO HeLa cells. Since a substitution of serine to proline is predicted to induce a protein folding defect, the most likely explanation is that VPS41 S285P has a structural defect that prevents formation of a functional HOPS complex.
A most striking finding in our studies is that patient-derived fibroblasts and VPS41 KO HeLa cells show a decreased lysosomal localization of mTORC1 and a constitutive nuclear localization of TFE3.
Accordingly, VPS41 KO cells and VPS41 S285P/R662* fibroblasts did not respond to starvation or subsequent 15 replenishment of nutrients. Neither VPS41 mutant could rescue this mTORC1/TFE3 phenotype in VPS41 KO cells. Defects in mTORC1 signaling have been reported in many neurodegenerative disorders, including Alzheimer and PD (55) . However, in contrast to the VPS41 phenotype these conditions show a decrease in lysosomal performance and an increase in mTORC1 activity. This is why development of therapeutics mostly focus on mTORC1 inhibition or TFEB/TFE3 activation (56, 57) . Our data show that lysosomes in VPS41 patient fibroblasts or KO cells are acidified and enzymatically active, thus in principle are functionally equipped. However, the transfer of endocytosed and autophagic cargo to these active lysosomes is compromised. A possible explanation for the mTORC1/TFE3 phenotype is therefore that lysosomes sense that they are deprived of nutrients even in nutrient-rich conditions. This 'starvation' scenario predicts that other factors blocking late endosome -lysosome fusion also lead to the mTORC1/TFE3 phenotype. Indeed, TFE3 translocates to the nucleus when cells are treated with chloroquine (50), which recently was shown to cause a block in late endosome -lysosome fusion (58) . Also inhibition of lysosomal proteases and thereby suppressing degradation of the lysosomal content results in mTORC1 inhibition and autophagy initiation (56, 59) . Moreover, we found that knockout of the HOPS components VPS11 or VPS18, also leads to TFE3 translocation and increased LC3-II levels, independent of nutrient status, whereas previously a link between VPS39 and mTORC1 signaling was reported (60) . These data indicate that a defect in HOPS function generally leads to mTORC1 inhibition.
The mTORC1 dissociation observed in VPS41 patient and KO cells induced a continuous nuclear localization of TFE3. TFE3 is part of the MiTF/TFE family of transcription factors that also comprises TFEB (61) . Similarly to TFEB, TFE3 translocates to the nucleus upon nutrient starvation and binds CLEAR elements in promotors of autophagic and lysosomal genes (49, 62) . Previous studies had already shown that depletion of VPS41 decreases HOPS-dependent fusion between autophagosomes and endolysosomes, resulting in accumulation of LC3-positive autophagosomes (63) . We here recapitulated this finding in HeLa VPS41KO cells. Moreover, in HeLa, A549 and PC12 VPS41 KO cells we found by EM an increase in number of autophagosomes (data not shown). Together these data show that depletion of VPS41 increases LC3 levels by increased protein synthesis as well as decreased lysosomal clearance. In contrast to VPS41 KO cells, LC3-II protein levels in patient-derived fibroblasts were not enhanced.
Possibly, the high variability between primary cells obscures changes in LC3-II levels. Alternatively, patient cells may have developed compensatory protective mechanisms against a block in clearance of autophagosomes.
By immuno-EM we found no effect on the concentration of LAMP-1 or LAMP-2 in lysosomal membranes. Also, cathepsin B and cathepsin D were readily activated, marking their presence in the lysosomes. By contrast, a short pulse of Dextran (2 hours) showed a decrease in delivery of endocytosed cargo to enzymatically active lysosomes. Since resident lysosomal proteins have half-lives of several days, this suggests that the absence of HOPS causes a delay rather than a block in cargo delivery. Indeed, prolonged incubation times (72 hours) showed similar co-localization levels of Dextran with SiR-Lysosome cathepsin D in VPS41 KO compared to VPS41 WT cells (data not shown). Of note, since the continuous activation of TFE3 leads to an increase in biosynthesis of lysosomal proteins, we cannot rule out that potential defects in the kinetics or efficiency in transport of LAMPs and other lysosomal membrane proteins are compensated for by a higher production. Future studies using pulsechase live cell imaging and mass spectrometry on isolated lysosomes are required to address the kinetics of lysosomal membrane protein transport in VPS41 KO cells. Concurrent with a lack of HOPS function we found that transfer of endocytosed cargo from late endosomes to lysosomes is compromised in patient-derived fibroblasts. In the paternal VPS41 WT/S285P fibroblasts there was no endocytosis defect, indicating that the WT allele compensates for VPS41 S285P function. In the maternal VPS41 WT/R662* fibroblasts, we did find a defect in transfer of endocytosed cargo to lysosomes, but this was not accompanied by the mTORC1/TFE3 phenotype. Cells were still able to respond to nutrient starvation and re-stimulation, indicating that the overall defect in lysosomal fusion is less severe than in patient cells and that the combined input of endocytic and autophagy cargo into lysosomes is sufficient to activate the mTORC1 complex.
Independent of HOPS, VPS41 is required for formation of secretory granules as well as transport of lysosomal membrane proteins via the ALP/LAMP-carrier pathway (18, 19, 23, 64) . Both functions depend on the interaction of VPS41 with AP-3(20-24). By co-IP we found that VPS41 S285P still binds AP-3. In addition, VPS41 S285P was able to rescue the secretion phenotype when expressed in VPS41 KO PC12 cells.
These data indicate that HOPS-independent functions of VPS41 are not significantly affected in patient cells due to the expression of the paternal VPS41 S285P allele. Notably, since VPS41 knockout mice are embryonic lethal (14) , the HOPS-independent functions of VPS41 S285P may be a vital factor for the survival of the patients. VPS41 was previously reported to confer neuroprotection in both C. elegans and mammalian models for PD (32) (33) (34) (35) . Overexpression of α-synuclein results in degeneration of dopaminergic neurons, which is prevented by simultaneous overexpression of human VPS41. Both the WD40 and CHCR domain of VPS41 are necessary for this neuroprotection (32, 34) , which are mutated in VPS41 S285P and VPS41 R662* , respectively. We found that transgenic nematodes co-expressing hVPS41 WT with either VPS41 S285P or VPS41 R662* retained the neuroprotective effect, resulting in a decrease in neurodegeneration. However, co-expressing VPS41 S285P and VPS41 R662* did not result in neuroprotection and even exacerbated cell death. Since we found that the VPS41 patient cells completely lack HOPS function, the neurodegenerative phenotype in the nematodes is likely HOPS related. Moreover, since HOPSdependent autophagosome-lysosome fusion is important for clearance of aggregated material, which particularly tends to accumulate in neurons over the course of ageing (17, 43, 45, 47) , overexpression of VPS41 in the C. elegans model possibly results in increased clearance of aggregated or misfolded proteins through autophagy. The intersection of lysosomal dysfunction and neurodegeneration has become a critical junction in the mechanistic underpinnings of PD (65) . This is best exemplified by the relationship between homo-vs. heterozygous inheritance of mutations in the Gaucher's disease associated gene, GBA1, which has become the most prevalent genetic risk factor for PD (66) . In the context of these results, it is tempting to speculate that an increased understanding of autolysosomal trafficking defects in VPS41 patient cells may serve to inform therapeutic strategies for neurodegenerative disorders as well(35).
Currently, patients with mutations in HOPS core components VPS11, VPS16 and VPS33A have been reported in literature, which all show a neurodegenerative phenotype (11, (67) (68) (69) (70) (71) (72) (73) (74) . Moreover, during our studies, a third patient with compound heterozygote mutations in VPS41 was identified (Personal communication by I. Stolte-Dijkstra, University Medical Center Groningen), bearing the VPS41 R662* mutation as well as a missense mutation (VPS41 H466R ), and displaying a similar neurological phenotype.
By western blot the VPS41 protein levels were markedly decreased in the patient-derived fibroblasts and similar TFE3 nuclear translocation was observed (data not shown), indicating that this patient also suffers from a loss of HOPS function.
In summary, our data suggest that the VPS41 patients may represent a novel class of lysosomal disorders in which lysosomes are enzymatically active but, due to a trafficking defect, insufficiently reached by nutrients, causing continuous 'starved' lysosomes. Interestingly, this results in an inhibition of mTORC1 as opposed to the hyperactivity of mTORC1 seen in many other neurodegenerative diseases. (75) (76) (77) . These observations are of particular importance with regards to the design of a possible treatment of HOPS related disorders (69, 70, 73, 78, 79) .
Methods and Materials
Identification of VPS41 variants
Whole exome sequencing was performed on both affected siblings and their father. Briefly, total leukocyte DNA was enriched using the Agilent SureSelect Human All Exon Variants were confirmed by Sanger sequencing according to standard protocols in both siblings, their father and their mother.
Antibodies and Reagents
Antibodies used in this study: mouse anti-LAMP-1 CD107a (555798, BD Pharmingen), rabbit anti-LC3 680RD goat anti-rabbit IgG (925-68071, LI-COR), goat anti-mouse IgG-ALEXA680 (A28183, ThermoFisher). As bridging antibody between mouse antibodies and protein-A gold, we used rabbit anti-mouse IgG (610-4120, Rockland). Antibodies were visualized for EM using protein-A gold conjugated to 10 or 15nm gold particles (Cell Microscopy Core, UMC Utrecht).
Endocytosis and lysosomal functionality assays
To study endocytosis, cells were incubated for 2h with 10.000MW Dextran-ALEXA Fluor 568 Blocks were infiltrated in 2.3M sucrose overnight at 4ᵒC, mounted on aluminum pins and frozen in liquid nitrogen (81) . To pick up ultrathin sections, a 1:1 mixture of 2.3M and 1.8% methylcellulose was used (82) .
CRISPR/Cas9 HeLa VPS41KO
Hela cells were transiently transfected with pSpCas9(BB)-2A-GFP (PX458)(83) encoding sgRNAs targeting VPS41 using X-tremeGENE (Merck) according to the manufacturers recommendation.
sgRNAs were designed with http://crispor.tefor.net/(84) and target coding sequences in the Nterminal region encoded by the third coding exon. The sgRNA used is sgRNA2
AAGTATTTCAGTTACCCCAT. GFP-positive cells were sorted using a FACSAria II flow cytometer (BD) and plated in 10 cm dishes. Colonies were picked from these plates after 1 week and expanded. To confirm VPS41 absence, total cell lysates were analyzed by Western blotting using mouse anti-VPS41 (SC-377271, Santa Cruz).
Co-Immunoprecipitation and Western blotting
Cells were seeded in 15cm dishes and transfected with the appropriate constructs as indicated in the respective figures and according to above mentioned transfection protocols. Cells were washed three times with ice-cold PBS and lysed using a CHAPS lysis buffer (50 mM Tris pH=7.5, 150mM NaCl, 5mM
MgCl2, 1mM DTT, 1% (w/v) CHAPS) complemented with protease and phosphatase inhibitor (Roche).
Cells were scraped, collected and spun down at 13000rpm for 15 min at 4°C. Protein levels were equalized between samples using a Bradford Protein Assay (Bio-Rad). 10% of the sample was saved as input control. The remainder of the samples was incubated for 1hr with uncoated protein G beads (Millipore) to remove a-specifically bound proteins. Beads were spun down and the supernatant was incubated with beads together with 2µg antibody against the prey. Samples were incubated overnight, extensively washed and eluted using SDS sample buffer and run on precast gradient (4-20%) gels (Bio-Rad 
Plasmids
The GFP-VPS41 constructs were cloned from hVPS41 cDNA (Origene) into a pDonor201 vector For the C. elegans experiments, the wild-type (wt) Pdat-1::hVPS41 construct was assembled as previously described 32 . Briefly, human VPS-41 cDNA was obtained from Open Biosystems (Huntsville, AL). Plasmid entry vectors were generated using Gateway Technology (Invitrogen) to clone PCR amplified constructs into pDONR221 to generate a hVPS41 entry clone. The hVPS41 entry clone was used to clone hVPS41 into the Gateway expression vector, pDEST-Pdat-1 42 . The mutant hVPS41 alleles were generated by site-directed mutagenesis of the Pdat-1::hVPS41 construct using the primers 5'-ATTCTACATCAGTGGACTTGCACCTCTCTGTGATCAGCTTGTTGTACTTCCGTATGTAAAGGAGATTTCAGAAAA AACGGAAAGAGAATACTGTGCCAG and 5'-CTGGCACAGTATTCTCTTTCCGTTTTTTCTGAAATCTCCTTTACA TACGGAAGTACAACAAGCTGATCACAGAGAGGTGCAAGTCCACTGATGTAGAAT to generate the Pdat- backgrounds was analyzed. For all strains, three representative lines of each were selected for further analysis.
Dopaminergic neurodegeneration analysis in C. elegans
C. elegans dopaminergic neurons were analyzed for degeneration as previously described (32, 33) .
Briefly, synchronized progeny from the BY250, UA44, and experimental hVPS41 variant strains were produced from a 3-hour egg-lay and grown at 20°C. Animals were analyzed at days 7 and 10 posthatching (4-and 7-day-old adults). On the day of analysis, the 6 anterior dopaminergic neurons [4 CEP (cephalic) and 2 ADE (anterior deirid)] were examined in 30 adult hermaphrodite worms, which were immobilized on glass cover slips using 3mM levamisole and transferred onto 2% agarose pads on microscope slides.
In quantifying neurodegeneration, animals are scored as "normal" when a full complement of all 6
anterior dopaminergic neurons are present and the neuronal processes are fully intact, as previously reported (33, 85, 86) . In total, at least 90 adult worms (30 worms/trial x 3 trials = 90 total animals) were analyzed for each independent strain and at least 270 adult worms were analyzed for each independent transgenic strain (30 worms/trial x 3 independent transgenic lines x 3 trials = 270 total animals/construct). Values of each independent experiment were normalized to the BY250 control and representative analyses were averaged and statistically analyzed by Prism and One-Way ANOVA.
Protein purification
The appendage domain of rat AP- 
Statistics
Quantification of all western blots was performed using Fiji software (80) . Two-tailed Students t tests were performed to compare two samples whereas ANOVA was performed for comparison of multiple samples to analyze statistical significance. Data distribution was assumed to be normal, but this was not formally tested. All error bars represent the Standard Error of the Mean (SEM). The corpus callosum is thin with a saber-shape (yellow arrow) configuration (splenium more thinned than the genu and body). The shape remains consistent over time. The vermis is normal in configuration and size initially, but demonstrates volume loss on follow-up examinations (green arrows). There is delay in myelin maturation present on T1 and T2 weighted axial images (blue arrow on T2 shows lack of peripheral myelin (arborization) on initial examination. There is further myelin development over time (blue arrows), although myelin maturation is slow. The TE30 MRS is age appropriate at both 21 months of age and 4 years 7 months of age. By 4 years 7 months of age, peritrigonal gliosis (FLAIR, pink arrow) and volume loss is obvious. (B) Patient 2 (younger sibling) underwent 2 MRI studies. Top row: 4 years, 11 months; Bottom row: 9 years, 6 months. The corpus callosum is thin with a saber-shape (yellow arrow) configuration (splenium more thinned than the genu and body). The shape remains consistent over time. The vermis demonstrates volume loss on both examinations (green arrows). The dentate nuclei (pink arrows) are bright on both examinations. There is cerebellar hemispheric volume loss on both studies. Myelin maturation is minimally delayed on T2 weighted image at 4 years 11 months of age, but normal on follow up examination. The TE 144 MR Spectroscopy (MRS) and follow-up TE 30 MRS are both age appropriate. There is no peritrigonal gliosis, although there is slightly less white matter in the peritrigonal region than expected for age. There is iron deposition in the basal ganglia on FLAIR and T2 weighted images at 9 years 8 months of age (blue arrows). Iron deposition was also present in the subthalamic nuclei (not shown). 
Figure 3. Loss of VPS41 WT results in impaired HOPS dependent late endosome -lysosome fusion (A)
Immunoprecipitation (IP) on HeLa cells co-expressing GFP-empty vector (EV), GFP-VPS41 WT , GFP-VPS41 S285P or GFP-VPS41 R662* and FLAG-VPS18. GFP-VPS41 WT and GFP-VPS41 S285P show interaction with FLAG-VPS18. Interaction between GFP-VPS41 R662* and FLAG-VPS18 is almost completely lost. Note that the stopcodon in VPS41 R662* leads to a truncated protein of lower MW. n=3. Similar results were obtained for HA-VPS33A ( Figure S5 ). (B) Western Blot of primary fibroblasts derived from mother (VPS41 WT/R662* ), father (VPS41 WT/S285P ) or patient (VPS41 S285P/R662* ). Full-length VPS41 (FL VPS41) representing VPS41 WT and VPS41 S285P is observed in all cells. Truncated VPS41 R662* expressed in patient and maternal fibroblasts is not detected. (C) HeLa VPS41KO cells transfected with VPS41 WT -APEX2-V5, VPS41 S285P -APEX2-V5 or VPS41 R662* -APEX2-V5 constructs were labeled for LAMP-1 and V5 for immunofluorescence microscopy. All VPS41 variants co-localized with LAMP-1, indicating that VPS41 S285P and VPS41 R662* are recruited to late endosomes/lysosomes. Bars 10µm, zoom of squared area 1µm. (D) IP on Hela cells co-expressing VPS41 WT -APEX2-V5, VPS41 S285P -APEX2-V5 or VPS41 R662* -APEX2-V5 and FLAG-RAB7 or GFP-Arl8b. The IP was performed on FLAG or GFP respectively. All VPS41 variants interact with Rab7 and Arl8b (n=3). (E) Rescue experiments. HeLa VPS41KO cells transfected with VPS41 WT -APEX2-V5 showed a significant increase in colocalization between Dextran and SiR-Lysosome cathepsin D, indicating rescue of the endocytosis phenotype. Neither VPS41 variant could rescue HOPS complex functionality ( Figure S6A ) (n=3). Error bars represent the SEM. ***p<10 -4 ; one-ANOVA with Bonferroni correction for multiple comparisons. (F) VPS41 WT/WT , VPS41 WT/S285P . VPS41 WT/R662* and VPS41 S285P/R662* primary fibroblasts were incubated with Dextran-ALEXA568 and SiR-Lysosome cathepsin D for 2h and 3h respectively. Co-localization representing delivery of Dextran to enzymatically active lysosomes was decreased in VPS41 WT/R662* and VPS41 S285P/R662* cells, indicating reduced fusion efficiency between late endosomes and lysosomes ( Figure S6B ) (n=3). Error bars represent the SEM. **p<0.01, ***p<10 -4 ; one-ANOVA with Tukey's correction for multiple comparisons. (G) VPS41 WT/WT , VPS41 WT/S285P , VPS41 WT/R662* and VPS41 S285P/R662* fibroblasts were incubated with BSA-Au 5 for 2h and labeled for LAMP-1 (10 nm gold particles) for immuno-EM ( Figure  2D ). LAMP-1-positive lysosomes were scored positive or negative for BSA-Au 5 and the ratio between BSA + and BSAlysosomes was calculated. Both VPS41 WT/R662* and VPS41 S285P/R662* show a strong decrease in BSA + -lysosomes indicating a fusion defect between late endosomes and lysosomes. In steady state conditions (Non Treated (NT)) VPS41 S285P/R662* fibroblasts show less colocalization between mTORC1 and LAMP-1 positive compartments. mTORC1 does not respond to changes in nutrient status. VPS41 WT/WT , VPS41 WT/S285P and VPS41 WT/R662* show an appropriate mTORC1 response upon nutrient deprivation (-Amino Acids (-AA)) or stimulation (-AA, +AA) ( Figure S6, quantified Western blot of pulldown of AP3 incubated with HIS-6 VPS41 WT or VPS41 S285P . There is no difference in affinity between VPS41 WT and VPS41 S285P ( Figure S9 ). (B) PC12 cells VPS41 KO , or VPS41 KO transduced with HA-VPS41 WT or HA-VPS41 S285P lentivirus were washed and incubated for 30 min in Tyrode's solution containing 2.5 mM K+ (basal) or 90 mM K+ (stimulated). Cellular (C) and secreted (D) secretogranin II (SgII) were measured by quantitative fluorescence immunoblotting. Error bars represent the SEM. (n=3). *p<0.05, **p<0.01, ***p<0.001; secretion data analyzed by one-way ANOVA. 
